- Split View
-
Views
-
Cite
Cite
Braja Gopal Patra, Babak Soltanalizadeh, Nan Deng, Leqing Wu, Vahed Maroufy, Canglin Wu, W Jim Zheng, Kirk Roberts, Hulin Wu, Ashraf Yaseen, An informatics research platform to make public gene expression time-course datasets reusable for more scientific discoveries, Database, Volume 2020, 2020, baaa074, https://doi.org/10.1093/database/baaa074
- Share Icon Share
Abstract
The exponential growth of genomic/genetic data in the era of Big Data demands new solutions for making these data findable, accessible, interoperable and reusable. In this article, we present a web-based platform named Gene Expression Time-Course Research (GETc) Platform that enables the discovery and visualization of time-course gene expression data and analytical results from the NIH/NCBI-sponsored Gene Expression Omnibus (GEO). The analytical results are produced from an analytic pipeline based on the ordinary differential equation model. Furthermore, in order to extract scientific insights from these results and disseminate the scientific findings, close and efficient collaborations between domain-specific experts from biomedical and scientific fields and data scientists is required. Therefore, GETc provides several recommendation functions and tools to facilitate effective collaborations. GETc platform is a very useful tool for researchers from the biomedical genomics community to present and communicate large numbers of analysis results from GEO. It is generalizable and broadly applicable across different biomedical research areas. GETc is a user-friendly and efficient web-based platform freely accessible at http://genestudy.org/
Introduction
Over the past few decades, substantial funding and resources have been invested to generate biomedical datasets at many levels, ranging from nucleic acid and gene level to population level, in order to understand, treat and prevent various diseases, and protect public health. Based on data sharing policies of National Institute of Health (NIH) and other government agencies, many of aforementioned datasets are required to be shared with the general research communities. Consequently, vast amounts of biomedical data are being accumulated in databases and data repositories. However, use or reuse of these existing datasets for research by third parties is still not common as expected.
Gene expression data from various diseases under different experimental conditions are mostly deposited in the NIH/NCBI-sponsored Gene Expression Omnibus (GEO) data repository (1). Like many of the biomedical databases, GEO was originally created as a data repository to comply with the data sharing policies. Often, these data sharing platforms are designed and organized for easy and convenient data submission by experimentalists, but not friendly for data retrieval and analysis. Further, it is not easy to identify the particular datasets to address a particular biological question for a specific disease from GEO, since the experimental design and study description are documented in an unstructured free text. Hence, it is necessary to use text mining and natural language processing (NLP) technologies to restructure the existing repository so that datasets can be findable, accessible and reusable.
This article describes a web-based platform that addresses the difficulties in finding, accessing, reusing biomedical datasets, specifically from GEO, as well as the difficulties in finding and forming collaborations. The novel platform, named as Gene Expression Time-Course Research (GETc) platform (http://genestudy.org/), is built on top of an analytical method based on the ordinary differential equation (ODE) model for analyzing time-course gene expression data. GETc offers the following services and functions:
Hosts time-course gene expression datasets from GEO annotated with disease and cell types.
User-friendly navigation and searching functions.
Hosts analysis results of the time-course gene expression datasets produced by the ODE analytic pipeline.
Recommends relevant datasets for users based on their research interests.
Recommends relevant papers and collaborators for each dataset hosted in the platform.
The rest of the article is organized as follows: Section 2 discusses the background of the analytic pipeline and recommendation systems. Section 3.1 presents datasets used for developing the GETc platform. Section 3.2 describes the methodology used for analytic pipeline, recommendation systems and platform implementation. Section 4 describes and discusses the results. Finally, conclusions are presented in Section 5.
Background
In this section, we present the three main parts of our work, (i) repositories developed for archiving datasets in the biomedical domains and their metadata, (ii) an analytic pipeline developed for analyzing gene data and (iii) dataset, literature and collaborator recommendation systems.
Dataset repositories
It is a growing trend among the researchers to make their data publicly available for reproducibility and data reusability. Many repositories and knowledge bases have been established for different types of data in many doma-ins. GEO(www.ncbi.nlm.nih.gov/geo/), UKBioBank(www.ukbiobank.ac.uk/), ImmPort(www.immport.org/home) and TCGA(portal.gdc.cancer.gov) are a few examples of repositories in the biomedical domain. DATA.GOV archives the U.S. Government’s open data from agriculture, climate, education, etc. for research use. However, users from the biomedical community have to visit and search each repository separately to find data for their research, which can be time-consuming and hectic.
DataMed(datamed.org) started an initiative to solve the above issue for the biomedical community by combining biomedical repositories and enhancing the query searching using advanced NLP techniques (2, 3). DataMed indexes and searches diverse categories of biomedical datasets (3). DataCite is another data discovery index, which includes 16 187 835 works from many different domains (4). However, these repositories do not provide either insight of data or help to find collaborators, which are still challenging tasks to accomplish.
Analytic pipelines for gene expression data
The study of gene regulation related to different biological functions is critical to understand the underlying mechanism of each function, such as cell growth, division, development and response to environmental stimulus. In addition, gene regulatory networks (GRN) have been shown useful for investigating the interaction among genes involved in a biological process, or genes responsive to an external stimulus. There are many computational approaches in the literature for inferring GRNs from gene expression data; for example, information theory models (5–7), Boolean networks (8–11) and Bayesian networks (12–15). However, these approaches are either not efficient in describing dynamic regulations between genes or restricted to small-scale networks. Meanwhile, responses to environmental stimulus, such as immune response to viral infection or response to aberrant activation of a particular pathway, are dynamic processes and require deliberate analysis of time-course gene expression data, which in turn is an ultra-high dimensional problem and needs the use of advanced statistical and computational approaches developed. Therefore, we implement an alternative comprehensive approach that exploits ODE models and gene regulatory network analysis developed in (16–18). This model takes into account the dynamic and temporal behavior of genes, and learns the dynamic relation between genes, in the form of stimulator or inhibitor of each other. Genes (or probes) with significant expression level changes over time are identified as dynamic response genes. Then the top 3000 dynamic response genes are clustered into groups according to their expression pattern over time. Finally, a regulatory network is established by the ODE model (19).
Recommendation systems
A recommendation system is an enabling mechanism to overcome information overload. Literature in this area can be broadly grouped as content-based or collaborative filtering based recommendation systems. Next, we discuss literature related to developed recommendation systems.
Dataset recommendation
There are many dataset repositories in the biomedical domain and many datasets are added to each repository on a daily basis. For example, 34 datasets were added to GEO repository daily in 2019. Hence researchers are likely to be overwhelmed with the data available and they have to visit each repository for searching a dataset. The platforms like DataMed solved this problem and researchers only had to visit DataMed for searching the datasets. However, DataMed has not been updated recently. Again, the intent of search is always difficult to identify (20). A dataset recommendation system based on researcher’s profile may be helpful for information filtering. There were a few experiments performed on data linking (21–23) where similar datasets were clustered together using different semantic features. Most of these works were on linking the datasets with similar datasets rather than a dataset recommendation.
Literature recommendation
The usefulness of the literature recommendation can be stated by the acceptance of Google Scholar, Semantic Scholar, PubMed, etc. The CiteSeer project (24, 25) was the first of its kind to start research paper recommendation. Later, many scientific article recommendation systems were developed. Science Concierge is a content-based article recommendation system using distributional semantics (LSA) and the relevance feedback (Rocchio algorithm). It recommends articles for any number of input articles based on the 2015 Society of Neuroscience Conference articles (26). (27) proposed a citation-based collaborative filtering recommendation system for research articles using Jaccard similarity. Similar article recommendation systems have been developed using TF-IDF (28), topic modeling (29) and citation or author network analysis (30). TF-IDF was the most frequently applied weighting scheme for recommendation tasks (25).
SciMiner is a web-based platform for identifying gene names in text based on user input and provides literature from MEDLINE for the corresponding gene (31). A content-based PubMed article recommendation system, PURE, was developed using Expectation Minimization (32) and it recommends articles to users based on their preferred articles. (33) developed a probabilistic topic-based model for content similarity called ‘pmra’ on the publications from MEDLINE and this has been used as a related article search function in PubMed. Most of the proposed literature recommendation systems use embedding methods to convert text into vectors and calculate the similarity between articles.
Once a researcher finds a dataset suitable for his/her study, he/she may need literature available related to the dataset. A literature recommendation system for datasets may be a helpful tool for this scenario where researchers can get literature from PubMed for each dataset.
Collaborator recommendation
Academic collaborator recommendation has long been regarded as a useful application in the academic environment, which aims to find potential collaborators for a given researcher by exploiting big academic data. In the past few years, several works on collaborator recommendation have been proposed (34–37).
Mainly, co-author network information has been incorporated to enhance the collaboration recommendation (35, 37, 38). (38) proposed a random walk restart model on co-author order, latest collaboration time point and collaboration times. (37) developed a collaborator recommendation system using collaborative entity embedding developed using the topic words collected from the publications of researchers. The cross-domain collaborator recommender is another important aspect of this recommendation and (36) proposed a cross-domain collaborator recommendation using the co-author matching, topic matching and cross-domain topic learning.
(35) proposed CollabSeer based on the co-author network and lexical similarity. However, it is difficult for new researchers or students to get recommendation using the co-author network or lexical similarity as they do not have papers. (39) proposed a collaborator recommender for new researchers or students using input keywords, organizational relationship, ratings and activity level of the collaborators.
When a researcher finds suitable data for his/her study, the researcher may look for collaborators to work with on that dataset. In this scenario, a collaborator recommendation system for each dataset may be helpful.
Materials and methods
Data
GEO Metadata collection
GEO is one of the most popular public repositories for functional genomics data. As of 18 December 2019, there were 122 222 series of datasets available in GEO. Metadata of GEO datasets such as title, summary, date of publication and name of authors was collected from the GEO using a web crawler. The PMIDs of the articles associated with each dataset were also collected. Many datasets did not have associated articles.
Time-course dataset: This study was conducted for the time-course datasets from GEO, however, the time-course datasets were not identified explicitly in the GEO websites. The time-course datasets can be identified manually by reading the dataset descriptions or scanning the associated data with it which is a time-consuming and tedious task. A keyword-based NLP method was applied for identifying time-course datasets. We implemented a regular expression-based approach to extract the time point information from the GEO metadata. For example, some phrases like ‘12 time points’, ‘7 developmental stages; harvest at 10 hrs, 12 hrs’, etc. were used to extract the time point information. The regular expression-based system was able to identify 167 datasets out of 200 random datasets with an accuracy of 83.5%. Further, a total of 555 datasets were filtered manually from 862 datasets identified by the above system for processing. More details on identifying time-course datasets can be found in (40). Once the datasets are identified, the GSE number were fed to the pipeline (Section 3.2.1) and it automatically retrieved the data and metadata information corresponding to GSE numbers. In addition to the time points, diseases, organisms or/and cell types were identified from the title and summary of the datasets. MetaMap (41) applied to the metadata, and the Human Disease Ontology (DOID) terms were detected from the annotated text for each dataset (42). Further, datasets can be filtered using both the cell type and diseases.
MEDLINE Articles
For developing dataset recommender, we collected the researcher’s publications from PubMed. MEDLINE articles were collected for developing literature and collaborator recommenders. MEDLINE articles were collected from PubMed which comprises more than 29 million biomedical and life science research articles. These articles consist of information such as title, abstract, authors, affiliations, Medical Subject Headings (MeSH) terms and publisher name.
However, the articles collected from PubMed contain a variety of topics related to biomedicine and life sciences which may not be suitable for building a recommendation system for datasets in GEO. Further, the articles before 1998 were removed as the research on micro-array data started during that year (43). The datasets that are related to gene expressions and articles collected from PubMed contain a variety of topics. Thus, a MeSH term-based filtering method was implemented to remove unrelated articles from the whole MEDLINE articles. The details of the filtering method can be found in (43). A total of 770 537 articles were utilized for developing literature and collaborator recommendations.
Methods
Analytic pipeline for time-course gene expression data
We integrated the series of statistical and modeling methods for the time-course gene expression data into an analytic pipeline (19) which includes eight steps as mentioned in Figure 1.
The final analysis results of the pipeline can be reported as the initial bioinformatics findings for narrowing down the analysis and framing scientific questions, toward new collaborative publications. We could apply the pipeline to each of the time-course gene expression datasets under one experimental or biological condition. Furthermore, simple comparison functions between two or more datasets across experimental conditions and/or from different studies are currently under development for the pipeline. We published the source code of the analytic pipeline, so others can use the pipeline and expand its functionalities.(github.com/j142857z/Pipeline (Original code)),(github.com/AutumnTail/Pipeline (Updated code)).
Recommendation systems
Data Recommendation: Data recommendation is an essential part of the GETc platform. The dataset recommendation function recommends datasets to researchers based on their publications. The datasets used for this recommendation system contain data not only from GEO but also from other sources such as TCGA, ArrayExpress, SRA and Clinical Trails. We used only textual information of datasets (title and summary) and publications (title and abstract).
A researcher may have multiple research interests. To identify the research interests, we implemented a non-parametric clustering algorithm named Dirichlet process mixture model (DPMM). More details on DPMM and its parameter tuning for obtaining better number of clusters can be found in (44). Each researcher had to provide name and curriculum vitae (CV)/list of publications to get dataset recommendation. Researcher’s names were searched in PubMed to get publications (title, abstract, year of publication). This search may result publications from other researchers with the same name which was solved by searching the title of the publication from PubMed in the CV/list of publications provided by the researcher. Finally, publications of the authors were clustered using DPMM to obtain the research topics. For each topic, datasets can be recommended by calculating cosine similarity of research field/cluster vector and dataset vectors. The detailed methodology and evaluation can be found in our previous publication on dataset recommendation (44).
Literature Recommendation: The literature recommendation system recommends literature for datasets. The most similar literature for a dataset can be determined simply by comparing the cosine similarity of the dataset vector and paper vectors. For developing the literature recommendation system in GETc, we used BM25 as it resulted in better precision at 10 compared to other embedding methods such as TF-IDF, word2vec and doc2vec (43). Finally, we used the title based weighted re-ranking and text normalization methods to improve the retrieved results. The detailed methods, experiments and results can be found in our previous publication (43).
Collaborator Recommendation: For each dataset, the recommendation system suggests some collaborators based on the recommended literature. We can say that the authors of the top similar literature for a dataset can be suitable collaborators to work with on that dataset. The authors of the similar articles may have experience working on the dataset and already published articles using it. Further, the collaborators may be recommended for each dataset by ranking the unique authors of the retrieved similar articles. For a dataset (d), the score for each unique author of similar articles can be calculated using Equation (1).
where AuthorScorei is the score for ith author calculated over all the retrieved similar articles (|$P = {P_0, P_1, ...P_n}$|) for d. n is the number of total retrieved article for d. SimScorej is the similarity score of d and jth article (Pj).
Higher weights were provided to the first and last authors of each similar article whereas less weights were provided to all other authors. Finally, the authors with the highest scores were recommended as the collaborators for d.
The top 1000 recommended publications from the above literature recommender for a single dataset were used for identifying collaborators for that dataset. Furthermore, authors’ affiliations provided in papers were parsed using the affiliation_parser(github.com/titipata/affiliation_parser) package and the distance between the recommended collaborators’ and the user’s current location was calculated using geopy(geopy.readthedocs.io) package to show a distance-based relevance of user and collaborators.
GETc Platform
In this work, we developed an interactive web-based platform, called GETc, to facilitate collaboration and sharing of the analytic results of our pipeline on time-course gene expression data from GEO to the general research community. We have identified 555 time-course gene expression datasets with more than 7 time points from GEO. We applied our analytic pipeline on 37 of those datasets (results in Section 4). The output of the analytic pipeline for each dataset is folder of files containing intermediate and final analytic results, tables, graphics/plots and documents. The output also includes an automatically generated analysis report for each dataset.
Platform users could interactively search, browse and identify particular datasets and corresponding results of interest. They can visualize and review the analysis results including figures and tables, which can be easily downloaded via the platform web-based user-interface. For the unprocessed time-course gene expression datasets included in the platform, users can request to execute the pipeline. The platform also provides its users with recommendations by employing the recommendation systems described in Section 3.2.2. It recommends literature for time-course gene expression datasets, potential collaborators for extracting scientific insights from the analytic results. It also recommends datasets to researchers. Figure 2 shows the overview of GETc platform. GETc platform executes the tasks mentioned inside the green box.
Users of the platform can search for a time-course dataset using keywords and phrases and see the literature available, significant gene lists, gene clusters and prospective collaborators for that dataset. A screenshot of search and view dataset functionalities is shown in Figure 3. The dataset can be searched if any of the searched keywords matched with the dataset id, title, abstract or platform organism. The datasets retrieved can be filtered using disease or cell type provided on the left side tree view or right side pie charts. The disease types are extracted from human disease ontology (40).
Results and discussion
The results of the analytic pipeline which we applied on 37 time-course gene expression cancer datasets from GEO are presented in Table A1. For each dataset with different conditions, the table shows the number of DRGs, number of GRMs, number of time points, cancer type, cell line, the organism, vitro or ex vitro or in vitro or in vivo and species (human or mouse/rats species). MCF10A, MCF7, HeLa and other widely used cell lines are tested in these datasets. These cells lines are originated from various types of cancers such as breast cancer, cervical cancer and leukemia. Also, treatments in these datasets target several essential cancer pathways, such as NFkB, EGFR and hedgehog. These classifications will help researchers perform meta-analyses to identify common/key genes and GRN in a certain type of cancer.
Evaluating recommendation systems are challenging because no benchmark nor prior true annotation exists for either dataset recommendation or dataset-driven literature recommendation. For that reason, we performed a manual evaluation by asking expert human judges to rate the recommendation of systems using one to three ‘stars’ scale based on the relevance (1: not relevant, 2: partially relevant, 3: most relevant).
We evaluated the recommendation systems using strict and partial precision at 10 (P@10). Strict considers only 3-star, while partial considers both 2- and 3-star results. The developed dataset recommendation system was evaluated with five judges who have worked on the datasets before. The system obtained P@10 (strict) and P@10 (partial) of 0.61 and 0.78, respectively. For the literature recommendation, we considered 36 datasets for evaluation and the human judges have already worked on these datasets earlier. The proposed system obtained 0.80 and 0.87 of P@10 (strict) and P@10 (partial), respectively.
No gold standard dataset for evaluating collaborator recommendation is available to date. Similar to literature recommendation, evaluating our collaborator recommendation system was a challenging task, as it requires time to work with collaborators and only then they can provide feedback for system’s output. We are currently working with additional multiple collaborators to evaluate the output of the system and generate feedback that we can use to assess the system’s quality in the future.
A screenshot of literature (top right corner) and collaborator (bottom right corner) recommendations for dataset GSE14 103 is provided in Figure 4. For a selected dataset on the platform UI, the literature recommendation system will generate a list of related papers recommended for users. The recommended list of collaborators can be sorted by name or distance. We have a plan to implement a search function which will allow users to search for collaborators based on the preferred city.
We believe the functions of GETc are very useful for researchers from the biomedical genomics community to present and communicate large numbers of analysis results. In addition to datasets from GEO, we are currently expanding the platform with new time-course datasets from other repositories such as TCGA, SRA and ImmPort. We applied the ODEs in the process of constructing the high-dimensional gene regularity network where having at least 8-time points was essential for the identifiability of the corresponding model. Thus, only datasets with more than or equal to 8-time points can be processed with our pipeline.
Conclusion
In this work, we developed a novel research platform called GETc for sharing data and analytic results of time-course gene expression datasets from GEO to improve the dataset reusability. It is built on top of an analytical method based on the ODE model for analyzing time-course gene expression data. GETc platform provides means to efficiently search and retrieve data, results, and facilitate collaboration through recommendation of related literature and potential collaborators corresponding to datasets. This platform also hosts a dataset recommendation system which will help researchers in biomedical domain to search datasets based on their publications. This will hopefully lead to better data reuse experience. We believe that the proposed novel idea and computational platform could also be applied to other types of data from different databases or data repositories.
Acknowledgement
We thank Dr H.M and other members from GEO Big Data Working Group at the Center for Big Data in Health Sciences (CBD-HS) for suggestions and comments on designing platform that greatly improved the website.
Funding
This project is mainly supported by the Center for Big Data in Health Sciences (CBD-HS) at School of Public Health, University of Texas Health Science Center at Houston (UTHealth), and partially supported by grants National Institute of Health (R01 AI087135, 1R01AG066749-01, 1UL1TR003167-01), Cancer Prevention and Research Institute of Texas (CPRIT RP170668) at UTHealth.
Conflicts of interest. None declared.
Appendix
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
1 | GSE1864 | 11 | Breast cancer | ZR-75.1 | ivr | HS | 17β-estradiol | 1272 | 85 |
17β-estradiol (dye swap) | 1145 | 34 | |||||||
2 | GSE3113 | 8 | Colorectal carcinoma | EcR-RKO/KLF4 | ivr | HS | Ponesterone | 3349 | 44 |
Control | 1589 | 50 | |||||||
3 | GSE770 | 10 | Prostate adenocarcinoma | LNCaP C4-2 | ivr | HS | Irradiation | 4227 | 72 |
4 | GSE1640 | 10 | Kaposi’s sarcoma | BCBL-1 | ivr | HS | Cidofovir rep1 | 473 | 146 |
Cidofovir rep2 | 453 | 137 | |||||||
Cidofovir rep3 | 301 | 164 | |||||||
Control rep1 | 643 | 125 | |||||||
Control rep2 | 504 | 121 | |||||||
Control rep3 | 568 | 142 | |||||||
5 | GSE9048 | 14 | N/A | Embryonic stem | ivr | MM | HDRep1 | 21 349 | 30 |
HDRep2 | 21 349 | 37 | |||||||
HD_LIF | 20 209 | 36 | |||||||
6 | GSE9854 | 10 | Osterosarcoma | U2OS | ivr | HS | GFP | 6400 | 84 |
HIC1 | 7062 | 61 | |||||||
7 | GSE14103 | 8 | Colorectal carcinoma | HCT116 | ivr | HS | Nocodazole | 6295 | 33 |
8 | GSE17018 | 9 | stomach | GIST-T1 | ivr | HS | Imatinib mesylat Rep1 | 13 121 | 42 |
9 | Imatinib mesylat Rep2 | 13 121 | 42 | ||||||
8 | Imatinib mesylat Rep3 | 23 002 | 34 | ||||||
9 | GSE20361 | 8 | Breast cancer | MCF-7 | ivr | HS | 17β-estradiol | 20 | |
10 | GSE20988 | 8 | Mediastinal (thymic) large B-cell lymphoma | K1106 | ivr | HS | JAK2 inhibitor | 4766 | 46 |
11 | GSE22955 | 16 | Breast cancer | SUM-225 | ivr | HS | HER-2 inhibitor CP724,714 | 11 725 | 84 |
12 | GSE23135 | 16 | Breast cancer | MCF-10A | ivr | HS | Gfitinib | 10 046 | 50 |
13 | GSE23136 | 16 | Breast cancer | MCF-10HER-2 | ivr | HS | Gfitinib | 12 184 | 49 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
1 | GSE1864 | 11 | Breast cancer | ZR-75.1 | ivr | HS | 17β-estradiol | 1272 | 85 |
17β-estradiol (dye swap) | 1145 | 34 | |||||||
2 | GSE3113 | 8 | Colorectal carcinoma | EcR-RKO/KLF4 | ivr | HS | Ponesterone | 3349 | 44 |
Control | 1589 | 50 | |||||||
3 | GSE770 | 10 | Prostate adenocarcinoma | LNCaP C4-2 | ivr | HS | Irradiation | 4227 | 72 |
4 | GSE1640 | 10 | Kaposi’s sarcoma | BCBL-1 | ivr | HS | Cidofovir rep1 | 473 | 146 |
Cidofovir rep2 | 453 | 137 | |||||||
Cidofovir rep3 | 301 | 164 | |||||||
Control rep1 | 643 | 125 | |||||||
Control rep2 | 504 | 121 | |||||||
Control rep3 | 568 | 142 | |||||||
5 | GSE9048 | 14 | N/A | Embryonic stem | ivr | MM | HDRep1 | 21 349 | 30 |
HDRep2 | 21 349 | 37 | |||||||
HD_LIF | 20 209 | 36 | |||||||
6 | GSE9854 | 10 | Osterosarcoma | U2OS | ivr | HS | GFP | 6400 | 84 |
HIC1 | 7062 | 61 | |||||||
7 | GSE14103 | 8 | Colorectal carcinoma | HCT116 | ivr | HS | Nocodazole | 6295 | 33 |
8 | GSE17018 | 9 | stomach | GIST-T1 | ivr | HS | Imatinib mesylat Rep1 | 13 121 | 42 |
9 | Imatinib mesylat Rep2 | 13 121 | 42 | ||||||
8 | Imatinib mesylat Rep3 | 23 002 | 34 | ||||||
9 | GSE20361 | 8 | Breast cancer | MCF-7 | ivr | HS | 17β-estradiol | 20 | |
10 | GSE20988 | 8 | Mediastinal (thymic) large B-cell lymphoma | K1106 | ivr | HS | JAK2 inhibitor | 4766 | 46 |
11 | GSE22955 | 16 | Breast cancer | SUM-225 | ivr | HS | HER-2 inhibitor CP724,714 | 11 725 | 84 |
12 | GSE23135 | 16 | Breast cancer | MCF-10A | ivr | HS | Gfitinib | 10 046 | 50 |
13 | GSE23136 | 16 | Breast cancer | MCF-10HER-2 | ivr | HS | Gfitinib | 12 184 | 49 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
1 | GSE1864 | 11 | Breast cancer | ZR-75.1 | ivr | HS | 17β-estradiol | 1272 | 85 |
17β-estradiol (dye swap) | 1145 | 34 | |||||||
2 | GSE3113 | 8 | Colorectal carcinoma | EcR-RKO/KLF4 | ivr | HS | Ponesterone | 3349 | 44 |
Control | 1589 | 50 | |||||||
3 | GSE770 | 10 | Prostate adenocarcinoma | LNCaP C4-2 | ivr | HS | Irradiation | 4227 | 72 |
4 | GSE1640 | 10 | Kaposi’s sarcoma | BCBL-1 | ivr | HS | Cidofovir rep1 | 473 | 146 |
Cidofovir rep2 | 453 | 137 | |||||||
Cidofovir rep3 | 301 | 164 | |||||||
Control rep1 | 643 | 125 | |||||||
Control rep2 | 504 | 121 | |||||||
Control rep3 | 568 | 142 | |||||||
5 | GSE9048 | 14 | N/A | Embryonic stem | ivr | MM | HDRep1 | 21 349 | 30 |
HDRep2 | 21 349 | 37 | |||||||
HD_LIF | 20 209 | 36 | |||||||
6 | GSE9854 | 10 | Osterosarcoma | U2OS | ivr | HS | GFP | 6400 | 84 |
HIC1 | 7062 | 61 | |||||||
7 | GSE14103 | 8 | Colorectal carcinoma | HCT116 | ivr | HS | Nocodazole | 6295 | 33 |
8 | GSE17018 | 9 | stomach | GIST-T1 | ivr | HS | Imatinib mesylat Rep1 | 13 121 | 42 |
9 | Imatinib mesylat Rep2 | 13 121 | 42 | ||||||
8 | Imatinib mesylat Rep3 | 23 002 | 34 | ||||||
9 | GSE20361 | 8 | Breast cancer | MCF-7 | ivr | HS | 17β-estradiol | 20 | |
10 | GSE20988 | 8 | Mediastinal (thymic) large B-cell lymphoma | K1106 | ivr | HS | JAK2 inhibitor | 4766 | 46 |
11 | GSE22955 | 16 | Breast cancer | SUM-225 | ivr | HS | HER-2 inhibitor CP724,714 | 11 725 | 84 |
12 | GSE23135 | 16 | Breast cancer | MCF-10A | ivr | HS | Gfitinib | 10 046 | 50 |
13 | GSE23136 | 16 | Breast cancer | MCF-10HER-2 | ivr | HS | Gfitinib | 12 184 | 49 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
1 | GSE1864 | 11 | Breast cancer | ZR-75.1 | ivr | HS | 17β-estradiol | 1272 | 85 |
17β-estradiol (dye swap) | 1145 | 34 | |||||||
2 | GSE3113 | 8 | Colorectal carcinoma | EcR-RKO/KLF4 | ivr | HS | Ponesterone | 3349 | 44 |
Control | 1589 | 50 | |||||||
3 | GSE770 | 10 | Prostate adenocarcinoma | LNCaP C4-2 | ivr | HS | Irradiation | 4227 | 72 |
4 | GSE1640 | 10 | Kaposi’s sarcoma | BCBL-1 | ivr | HS | Cidofovir rep1 | 473 | 146 |
Cidofovir rep2 | 453 | 137 | |||||||
Cidofovir rep3 | 301 | 164 | |||||||
Control rep1 | 643 | 125 | |||||||
Control rep2 | 504 | 121 | |||||||
Control rep3 | 568 | 142 | |||||||
5 | GSE9048 | 14 | N/A | Embryonic stem | ivr | MM | HDRep1 | 21 349 | 30 |
HDRep2 | 21 349 | 37 | |||||||
HD_LIF | 20 209 | 36 | |||||||
6 | GSE9854 | 10 | Osterosarcoma | U2OS | ivr | HS | GFP | 6400 | 84 |
HIC1 | 7062 | 61 | |||||||
7 | GSE14103 | 8 | Colorectal carcinoma | HCT116 | ivr | HS | Nocodazole | 6295 | 33 |
8 | GSE17018 | 9 | stomach | GIST-T1 | ivr | HS | Imatinib mesylat Rep1 | 13 121 | 42 |
9 | Imatinib mesylat Rep2 | 13 121 | 42 | ||||||
8 | Imatinib mesylat Rep3 | 23 002 | 34 | ||||||
9 | GSE20361 | 8 | Breast cancer | MCF-7 | ivr | HS | 17β-estradiol | 20 | |
10 | GSE20988 | 8 | Mediastinal (thymic) large B-cell lymphoma | K1106 | ivr | HS | JAK2 inhibitor | 4766 | 46 |
11 | GSE22955 | 16 | Breast cancer | SUM-225 | ivr | HS | HER-2 inhibitor CP724,714 | 11 725 | 84 |
12 | GSE23135 | 16 | Breast cancer | MCF-10A | ivr | HS | Gfitinib | 10 046 | 50 |
13 | GSE23136 | 16 | Breast cancer | MCF-10HER-2 | ivr | HS | Gfitinib | 12 184 | 49 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
14 | GSE18684 | 28 | Prostate adenocarcinoma | LNCaP | ivr | HS | R1881_Rep1-1 | 8666 | 41 |
28 | R1881_Rep1-2 | 9293 | 121 | ||||||
9 | R1881_Rep2-1 | 4272 | 49 | ||||||
9 | R1881_Rep2-2 | 4052 | 51 | ||||||
15 | GSE21618 | 8 | Breast cancer | MCF-7 | ivr | HS | TamR_Control | 6676 | 47 |
TamR_E2 | 4859 | 38 | |||||||
TamR_E2_Tamoxifen | 11 314 | 36 | |||||||
TamR_HRG | 14 764 | 38 | |||||||
TamR_HRG_Tamoxifen | 10 243 | 31 | |||||||
TamR_Tamoxifen | 10 345 | 35 | |||||||
WT_E2 | 7606 | 35 | |||||||
WT_E2_Rep1 | 8619 | 39 | |||||||
WT_E2_Rep2 | 3267 | 41 | |||||||
WT_E2_Tamoxifen | 6059 | 37 | |||||||
WT_HRG | 8370 | 34 | |||||||
WT_HRG_Rep1 | 11 724 | 32 | |||||||
WT_HRG_Rep2 | 9274 | 42 | |||||||
WT_HRG_Tamoxifen | 6093 | 35 | |||||||
WT_Tamoxifen | 3530 | 37 | |||||||
16 | GSE41072 | 19 | Acute T cell leukemia | Jurkar or Primary T cells | ivr | HS | Jurkat Roc | 14 382 | 44 |
12 | Tcell Roc | 8520 | 59 | ||||||
17 | GSE26002 | 8 | Glioblastoma | TRP mouse model | ivv | MM | TRPhet | 1328 | 45 |
18 | GSE38623 | 13 | Skin cancer | Mouse whole back skin | evv | MM | UVB | 11 225 | 104 |
19 | GSE29641 | 8 | Breast cancer | DU145; HT29; MCF7 | ivr | HS | Hypoxia | 6325 | 26 |
Hypoxia | 7651 | 29 | |||||||
Hypoxia | 8169 | 29 | |||||||
20 | GSE41034 | 8 | Diffuse large B-cell lymphoma | HBL-1 | ivr | HS | IkB kinase beta inhibitor MLN120B | 15 278 | 43 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
14 | GSE18684 | 28 | Prostate adenocarcinoma | LNCaP | ivr | HS | R1881_Rep1-1 | 8666 | 41 |
28 | R1881_Rep1-2 | 9293 | 121 | ||||||
9 | R1881_Rep2-1 | 4272 | 49 | ||||||
9 | R1881_Rep2-2 | 4052 | 51 | ||||||
15 | GSE21618 | 8 | Breast cancer | MCF-7 | ivr | HS | TamR_Control | 6676 | 47 |
TamR_E2 | 4859 | 38 | |||||||
TamR_E2_Tamoxifen | 11 314 | 36 | |||||||
TamR_HRG | 14 764 | 38 | |||||||
TamR_HRG_Tamoxifen | 10 243 | 31 | |||||||
TamR_Tamoxifen | 10 345 | 35 | |||||||
WT_E2 | 7606 | 35 | |||||||
WT_E2_Rep1 | 8619 | 39 | |||||||
WT_E2_Rep2 | 3267 | 41 | |||||||
WT_E2_Tamoxifen | 6059 | 37 | |||||||
WT_HRG | 8370 | 34 | |||||||
WT_HRG_Rep1 | 11 724 | 32 | |||||||
WT_HRG_Rep2 | 9274 | 42 | |||||||
WT_HRG_Tamoxifen | 6093 | 35 | |||||||
WT_Tamoxifen | 3530 | 37 | |||||||
16 | GSE41072 | 19 | Acute T cell leukemia | Jurkar or Primary T cells | ivr | HS | Jurkat Roc | 14 382 | 44 |
12 | Tcell Roc | 8520 | 59 | ||||||
17 | GSE26002 | 8 | Glioblastoma | TRP mouse model | ivv | MM | TRPhet | 1328 | 45 |
18 | GSE38623 | 13 | Skin cancer | Mouse whole back skin | evv | MM | UVB | 11 225 | 104 |
19 | GSE29641 | 8 | Breast cancer | DU145; HT29; MCF7 | ivr | HS | Hypoxia | 6325 | 26 |
Hypoxia | 7651 | 29 | |||||||
Hypoxia | 8169 | 29 | |||||||
20 | GSE41034 | 8 | Diffuse large B-cell lymphoma | HBL-1 | ivr | HS | IkB kinase beta inhibitor MLN120B | 15 278 | 43 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
14 | GSE18684 | 28 | Prostate adenocarcinoma | LNCaP | ivr | HS | R1881_Rep1-1 | 8666 | 41 |
28 | R1881_Rep1-2 | 9293 | 121 | ||||||
9 | R1881_Rep2-1 | 4272 | 49 | ||||||
9 | R1881_Rep2-2 | 4052 | 51 | ||||||
15 | GSE21618 | 8 | Breast cancer | MCF-7 | ivr | HS | TamR_Control | 6676 | 47 |
TamR_E2 | 4859 | 38 | |||||||
TamR_E2_Tamoxifen | 11 314 | 36 | |||||||
TamR_HRG | 14 764 | 38 | |||||||
TamR_HRG_Tamoxifen | 10 243 | 31 | |||||||
TamR_Tamoxifen | 10 345 | 35 | |||||||
WT_E2 | 7606 | 35 | |||||||
WT_E2_Rep1 | 8619 | 39 | |||||||
WT_E2_Rep2 | 3267 | 41 | |||||||
WT_E2_Tamoxifen | 6059 | 37 | |||||||
WT_HRG | 8370 | 34 | |||||||
WT_HRG_Rep1 | 11 724 | 32 | |||||||
WT_HRG_Rep2 | 9274 | 42 | |||||||
WT_HRG_Tamoxifen | 6093 | 35 | |||||||
WT_Tamoxifen | 3530 | 37 | |||||||
16 | GSE41072 | 19 | Acute T cell leukemia | Jurkar or Primary T cells | ivr | HS | Jurkat Roc | 14 382 | 44 |
12 | Tcell Roc | 8520 | 59 | ||||||
17 | GSE26002 | 8 | Glioblastoma | TRP mouse model | ivv | MM | TRPhet | 1328 | 45 |
18 | GSE38623 | 13 | Skin cancer | Mouse whole back skin | evv | MM | UVB | 11 225 | 104 |
19 | GSE29641 | 8 | Breast cancer | DU145; HT29; MCF7 | ivr | HS | Hypoxia | 6325 | 26 |
Hypoxia | 7651 | 29 | |||||||
Hypoxia | 8169 | 29 | |||||||
20 | GSE41034 | 8 | Diffuse large B-cell lymphoma | HBL-1 | ivr | HS | IkB kinase beta inhibitor MLN120B | 15 278 | 43 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
14 | GSE18684 | 28 | Prostate adenocarcinoma | LNCaP | ivr | HS | R1881_Rep1-1 | 8666 | 41 |
28 | R1881_Rep1-2 | 9293 | 121 | ||||||
9 | R1881_Rep2-1 | 4272 | 49 | ||||||
9 | R1881_Rep2-2 | 4052 | 51 | ||||||
15 | GSE21618 | 8 | Breast cancer | MCF-7 | ivr | HS | TamR_Control | 6676 | 47 |
TamR_E2 | 4859 | 38 | |||||||
TamR_E2_Tamoxifen | 11 314 | 36 | |||||||
TamR_HRG | 14 764 | 38 | |||||||
TamR_HRG_Tamoxifen | 10 243 | 31 | |||||||
TamR_Tamoxifen | 10 345 | 35 | |||||||
WT_E2 | 7606 | 35 | |||||||
WT_E2_Rep1 | 8619 | 39 | |||||||
WT_E2_Rep2 | 3267 | 41 | |||||||
WT_E2_Tamoxifen | 6059 | 37 | |||||||
WT_HRG | 8370 | 34 | |||||||
WT_HRG_Rep1 | 11 724 | 32 | |||||||
WT_HRG_Rep2 | 9274 | 42 | |||||||
WT_HRG_Tamoxifen | 6093 | 35 | |||||||
WT_Tamoxifen | 3530 | 37 | |||||||
16 | GSE41072 | 19 | Acute T cell leukemia | Jurkar or Primary T cells | ivr | HS | Jurkat Roc | 14 382 | 44 |
12 | Tcell Roc | 8520 | 59 | ||||||
17 | GSE26002 | 8 | Glioblastoma | TRP mouse model | ivv | MM | TRPhet | 1328 | 45 |
18 | GSE38623 | 13 | Skin cancer | Mouse whole back skin | evv | MM | UVB | 11 225 | 104 |
19 | GSE29641 | 8 | Breast cancer | DU145; HT29; MCF7 | ivr | HS | Hypoxia | 6325 | 26 |
Hypoxia | 7651 | 29 | |||||||
Hypoxia | 8169 | 29 | |||||||
20 | GSE41034 | 8 | Diffuse large B-cell lymphoma | HBL-1 | ivr | HS | IkB kinase beta inhibitor MLN120B | 15 278 | 43 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
21 | GSE23137 | 16 | Breast cancer | MCF-10HER-2 | ivr | HS | HER-2 inhibitor CP724,714 | 11 469 | 140 |
22 | GSE23138 | 16 | Breast cancer | MCF-10A | ivr | HS | HER-2 inhibitor CP724,714 | 8811 | 120 |
23 | GSE23139 | 16 | Breast cancer | MCF-10HER-2/E7 | ivr | HS | HER-2 inhibitor CP724,714 | 9221 | 96 |
24 | GSE32869 | 11 | Pancreas adenocarcinoma | AR42J | ivr | RN | Gastrin | 7181 | 81 |
12 | Control | 6594 | 92 | ||||||
11 | Gastrin | 5515 | 105 | ||||||
12 | Control | 6282 | 144 | ||||||
25 | GSE41491 | 8 | Breast cancer | DU145; HT29; MCF7 | ivr | HS | Hypoxia | 6127 | 27 |
Hypoxia | 7406 | 30 | |||||||
Hypoxia | 8011 | 24 | |||||||
26 | GSE44700 | 12 | B-cell Precursor leukemia cell line | BLaER1 | ivr | HS | E2 treatment rep1 | 31 583 | 48 |
E2 treatment rep2 | 23 767 | 68 | |||||||
27 | GSE46045 | 14 | Desmoplastic cerebellar medulloblastoma | Daoy | ivr | HS | Control_median | 7176 | 216 |
EGF_median | 15 659 | 48 | |||||||
EGF_SHH_median | 17 972 | 51 | |||||||
SHH_median | 10 770 | 237 | |||||||
28 | GSE49583 | 8 | Pancreatic carcinoma | Primary pancreatic stellate cells | ivr | HS | Tumor-cell supernatant | 4469 | 48 |
29 | GSE49584 | 8 | Pancreatic carcinoma | MiaPaca2 | ivr | HS | Control | 5441 | 44 |
30 | GSE49586 | 9 | Pancreatic carcinoma | MiaPaca2 | ivr | HS | Stellate-cell supernatant | 14 601 | 37 |
31 | GSE50624 | 8 | Acute T cell leukemia | Jurkat | ivr | HS | CDK7 inhibitor | 30 013 | 9 |
CDK7 inhibitor | 29804 | 13 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
21 | GSE23137 | 16 | Breast cancer | MCF-10HER-2 | ivr | HS | HER-2 inhibitor CP724,714 | 11 469 | 140 |
22 | GSE23138 | 16 | Breast cancer | MCF-10A | ivr | HS | HER-2 inhibitor CP724,714 | 8811 | 120 |
23 | GSE23139 | 16 | Breast cancer | MCF-10HER-2/E7 | ivr | HS | HER-2 inhibitor CP724,714 | 9221 | 96 |
24 | GSE32869 | 11 | Pancreas adenocarcinoma | AR42J | ivr | RN | Gastrin | 7181 | 81 |
12 | Control | 6594 | 92 | ||||||
11 | Gastrin | 5515 | 105 | ||||||
12 | Control | 6282 | 144 | ||||||
25 | GSE41491 | 8 | Breast cancer | DU145; HT29; MCF7 | ivr | HS | Hypoxia | 6127 | 27 |
Hypoxia | 7406 | 30 | |||||||
Hypoxia | 8011 | 24 | |||||||
26 | GSE44700 | 12 | B-cell Precursor leukemia cell line | BLaER1 | ivr | HS | E2 treatment rep1 | 31 583 | 48 |
E2 treatment rep2 | 23 767 | 68 | |||||||
27 | GSE46045 | 14 | Desmoplastic cerebellar medulloblastoma | Daoy | ivr | HS | Control_median | 7176 | 216 |
EGF_median | 15 659 | 48 | |||||||
EGF_SHH_median | 17 972 | 51 | |||||||
SHH_median | 10 770 | 237 | |||||||
28 | GSE49583 | 8 | Pancreatic carcinoma | Primary pancreatic stellate cells | ivr | HS | Tumor-cell supernatant | 4469 | 48 |
29 | GSE49584 | 8 | Pancreatic carcinoma | MiaPaca2 | ivr | HS | Control | 5441 | 44 |
30 | GSE49586 | 9 | Pancreatic carcinoma | MiaPaca2 | ivr | HS | Stellate-cell supernatant | 14 601 | 37 |
31 | GSE50624 | 8 | Acute T cell leukemia | Jurkat | ivr | HS | CDK7 inhibitor | 30 013 | 9 |
CDK7 inhibitor | 29804 | 13 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
21 | GSE23137 | 16 | Breast cancer | MCF-10HER-2 | ivr | HS | HER-2 inhibitor CP724,714 | 11 469 | 140 |
22 | GSE23138 | 16 | Breast cancer | MCF-10A | ivr | HS | HER-2 inhibitor CP724,714 | 8811 | 120 |
23 | GSE23139 | 16 | Breast cancer | MCF-10HER-2/E7 | ivr | HS | HER-2 inhibitor CP724,714 | 9221 | 96 |
24 | GSE32869 | 11 | Pancreas adenocarcinoma | AR42J | ivr | RN | Gastrin | 7181 | 81 |
12 | Control | 6594 | 92 | ||||||
11 | Gastrin | 5515 | 105 | ||||||
12 | Control | 6282 | 144 | ||||||
25 | GSE41491 | 8 | Breast cancer | DU145; HT29; MCF7 | ivr | HS | Hypoxia | 6127 | 27 |
Hypoxia | 7406 | 30 | |||||||
Hypoxia | 8011 | 24 | |||||||
26 | GSE44700 | 12 | B-cell Precursor leukemia cell line | BLaER1 | ivr | HS | E2 treatment rep1 | 31 583 | 48 |
E2 treatment rep2 | 23 767 | 68 | |||||||
27 | GSE46045 | 14 | Desmoplastic cerebellar medulloblastoma | Daoy | ivr | HS | Control_median | 7176 | 216 |
EGF_median | 15 659 | 48 | |||||||
EGF_SHH_median | 17 972 | 51 | |||||||
SHH_median | 10 770 | 237 | |||||||
28 | GSE49583 | 8 | Pancreatic carcinoma | Primary pancreatic stellate cells | ivr | HS | Tumor-cell supernatant | 4469 | 48 |
29 | GSE49584 | 8 | Pancreatic carcinoma | MiaPaca2 | ivr | HS | Control | 5441 | 44 |
30 | GSE49586 | 9 | Pancreatic carcinoma | MiaPaca2 | ivr | HS | Stellate-cell supernatant | 14 601 | 37 |
31 | GSE50624 | 8 | Acute T cell leukemia | Jurkat | ivr | HS | CDK7 inhibitor | 30 013 | 9 |
CDK7 inhibitor | 29804 | 13 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
21 | GSE23137 | 16 | Breast cancer | MCF-10HER-2 | ivr | HS | HER-2 inhibitor CP724,714 | 11 469 | 140 |
22 | GSE23138 | 16 | Breast cancer | MCF-10A | ivr | HS | HER-2 inhibitor CP724,714 | 8811 | 120 |
23 | GSE23139 | 16 | Breast cancer | MCF-10HER-2/E7 | ivr | HS | HER-2 inhibitor CP724,714 | 9221 | 96 |
24 | GSE32869 | 11 | Pancreas adenocarcinoma | AR42J | ivr | RN | Gastrin | 7181 | 81 |
12 | Control | 6594 | 92 | ||||||
11 | Gastrin | 5515 | 105 | ||||||
12 | Control | 6282 | 144 | ||||||
25 | GSE41491 | 8 | Breast cancer | DU145; HT29; MCF7 | ivr | HS | Hypoxia | 6127 | 27 |
Hypoxia | 7406 | 30 | |||||||
Hypoxia | 8011 | 24 | |||||||
26 | GSE44700 | 12 | B-cell Precursor leukemia cell line | BLaER1 | ivr | HS | E2 treatment rep1 | 31 583 | 48 |
E2 treatment rep2 | 23 767 | 68 | |||||||
27 | GSE46045 | 14 | Desmoplastic cerebellar medulloblastoma | Daoy | ivr | HS | Control_median | 7176 | 216 |
EGF_median | 15 659 | 48 | |||||||
EGF_SHH_median | 17 972 | 51 | |||||||
SHH_median | 10 770 | 237 | |||||||
28 | GSE49583 | 8 | Pancreatic carcinoma | Primary pancreatic stellate cells | ivr | HS | Tumor-cell supernatant | 4469 | 48 |
29 | GSE49584 | 8 | Pancreatic carcinoma | MiaPaca2 | ivr | HS | Control | 5441 | 44 |
30 | GSE49586 | 9 | Pancreatic carcinoma | MiaPaca2 | ivr | HS | Stellate-cell supernatant | 14 601 | 37 |
31 | GSE50624 | 8 | Acute T cell leukemia | Jurkat | ivr | HS | CDK7 inhibitor | 30 013 | 9 |
CDK7 inhibitor | 29804 | 13 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
32 | GSE52710 | 10 | Hodgkin lymphoma | L428 | ivr | HS | LNA-antimiR-9 | 3921 | 56 |
LNA-Scrable | 1732 | 66 | |||||||
33 | GSE15327 | 9 | Non-small cell lung cancer | NCI-H1975 | ivr | HS | H2O2 | 2446 | 75 |
Menadione | 8912 | 24 | |||||||
34 | GSE50988 | 23 | Osteosarcoma | U2OS | ivr | HS | Thymidine-nocodazol | 7763 | 792 |
20 | Thymidine rep1 | 18 894 | 166 | ||||||
24 | Thymidine rep2 | 9593 | 390 | ||||||
24 | Thymidine rep3 | 24 583 | 199 | ||||||
35 | GSE64073 | 17 | Breast cancer | MCF7 | ivr | HS | DHMEQ | 20 | 233 |
16 | HRG | 15533 | 102 | ||||||
16 | HRG + DHMEQ | 16 573 | 62 | ||||||
16 | HRG + LY294002 | 12 128 | 174 | ||||||
17 | LY294002 | 14 309 | 48 | ||||||
17 | Control | 6427 | 193 | ||||||
36 | GSE71721 | 11 | Burkitt lymphoma | Primary lymphoma | evv | HS | anti human IgM F(ab)2 fragment rep1 | 6294 | 58 |
10 | anti human IgM F(ab)2 fragment rep2 | 4479 | 62 | ||||||
10 | anti human IgM F(ab)2 fragment rep3 | 4479 | 62 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
32 | GSE52710 | 10 | Hodgkin lymphoma | L428 | ivr | HS | LNA-antimiR-9 | 3921 | 56 |
LNA-Scrable | 1732 | 66 | |||||||
33 | GSE15327 | 9 | Non-small cell lung cancer | NCI-H1975 | ivr | HS | H2O2 | 2446 | 75 |
Menadione | 8912 | 24 | |||||||
34 | GSE50988 | 23 | Osteosarcoma | U2OS | ivr | HS | Thymidine-nocodazol | 7763 | 792 |
20 | Thymidine rep1 | 18 894 | 166 | ||||||
24 | Thymidine rep2 | 9593 | 390 | ||||||
24 | Thymidine rep3 | 24 583 | 199 | ||||||
35 | GSE64073 | 17 | Breast cancer | MCF7 | ivr | HS | DHMEQ | 20 | 233 |
16 | HRG | 15533 | 102 | ||||||
16 | HRG + DHMEQ | 16 573 | 62 | ||||||
16 | HRG + LY294002 | 12 128 | 174 | ||||||
17 | LY294002 | 14 309 | 48 | ||||||
17 | Control | 6427 | 193 | ||||||
36 | GSE71721 | 11 | Burkitt lymphoma | Primary lymphoma | evv | HS | anti human IgM F(ab)2 fragment rep1 | 6294 | 58 |
10 | anti human IgM F(ab)2 fragment rep2 | 4479 | 62 | ||||||
10 | anti human IgM F(ab)2 fragment rep3 | 4479 | 62 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
32 | GSE52710 | 10 | Hodgkin lymphoma | L428 | ivr | HS | LNA-antimiR-9 | 3921 | 56 |
LNA-Scrable | 1732 | 66 | |||||||
33 | GSE15327 | 9 | Non-small cell lung cancer | NCI-H1975 | ivr | HS | H2O2 | 2446 | 75 |
Menadione | 8912 | 24 | |||||||
34 | GSE50988 | 23 | Osteosarcoma | U2OS | ivr | HS | Thymidine-nocodazol | 7763 | 792 |
20 | Thymidine rep1 | 18 894 | 166 | ||||||
24 | Thymidine rep2 | 9593 | 390 | ||||||
24 | Thymidine rep3 | 24 583 | 199 | ||||||
35 | GSE64073 | 17 | Breast cancer | MCF7 | ivr | HS | DHMEQ | 20 | 233 |
16 | HRG | 15533 | 102 | ||||||
16 | HRG + DHMEQ | 16 573 | 62 | ||||||
16 | HRG + LY294002 | 12 128 | 174 | ||||||
17 | LY294002 | 14 309 | 48 | ||||||
17 | Control | 6427 | 193 | ||||||
36 | GSE71721 | 11 | Burkitt lymphoma | Primary lymphoma | evv | HS | anti human IgM F(ab)2 fragment rep1 | 6294 | 58 |
10 | anti human IgM F(ab)2 fragment rep2 | 4479 | 62 | ||||||
10 | anti human IgM F(ab)2 fragment rep3 | 4479 | 62 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
32 | GSE52710 | 10 | Hodgkin lymphoma | L428 | ivr | HS | LNA-antimiR-9 | 3921 | 56 |
LNA-Scrable | 1732 | 66 | |||||||
33 | GSE15327 | 9 | Non-small cell lung cancer | NCI-H1975 | ivr | HS | H2O2 | 2446 | 75 |
Menadione | 8912 | 24 | |||||||
34 | GSE50988 | 23 | Osteosarcoma | U2OS | ivr | HS | Thymidine-nocodazol | 7763 | 792 |
20 | Thymidine rep1 | 18 894 | 166 | ||||||
24 | Thymidine rep2 | 9593 | 390 | ||||||
24 | Thymidine rep3 | 24 583 | 199 | ||||||
35 | GSE64073 | 17 | Breast cancer | MCF7 | ivr | HS | DHMEQ | 20 | 233 |
16 | HRG | 15533 | 102 | ||||||
16 | HRG + DHMEQ | 16 573 | 62 | ||||||
16 | HRG + LY294002 | 12 128 | 174 | ||||||
17 | LY294002 | 14 309 | 48 | ||||||
17 | Control | 6427 | 193 | ||||||
36 | GSE71721 | 11 | Burkitt lymphoma | Primary lymphoma | evv | HS | anti human IgM F(ab)2 fragment rep1 | 6294 | 58 |
10 | anti human IgM F(ab)2 fragment rep2 | 4479 | 62 | ||||||
10 | anti human IgM F(ab)2 fragment rep3 | 4479 | 62 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
37 | GSE15523 | 8 | Skin cancer | BJ NMyc | ivr | HS | N-MycER(delta-MbII) | 3875 | 44 |
N-MycER | 2741 | 54 | |||||||
38 | GSE17708 | 9 | Lung adenocarcinoma | A549 | ivr | HS | TGFb1 | 20 296 | 57 |
39 | GSE18817 | 8 | Diffuse large B-cell lymphoma | HBL-1 | ivr | HS | MLN120B | 11 865 | 51 |
40 | GSE34228 | 26 | Lung adenocarcinoma | PC9 | ivr | HS | Gefitinib | 30 565 | 73 |
41 | GSE21245 | 10 | Pancreatic adenocarcinoma | LNCaP | ivr | HS | Dihydrotestosterone miRNA array | 143 | 188 |
Dihydrotestosterone miRNA array | 13 636 | 93 | |||||||
42 | GSE34243 | 17 | N/A | Pgk12.1 | ivr | MM | Differentiation induction | 343 738 | 49 |
43 | GSE45958 | 8 | Breast cancer | Control | ivr | HS | 2gy Radiation | 56 560 | 44 |
6gy Radiation | 27191 | 46 | |||||||
R6gy | 43 650 | 46 | |||||||
44 | GSE76368 | 8 | Breast cancer | MCF-7 | ivr | HS | Starvation | 3229 | 51 |
45 | GSE84096 | 11 | Non-small cell lung cancer | NCI-H1975 | ev | HS | EGF | 9443 | 90 |
8 | Control | 7059 | 64 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
37 | GSE15523 | 8 | Skin cancer | BJ NMyc | ivr | HS | N-MycER(delta-MbII) | 3875 | 44 |
N-MycER | 2741 | 54 | |||||||
38 | GSE17708 | 9 | Lung adenocarcinoma | A549 | ivr | HS | TGFb1 | 20 296 | 57 |
39 | GSE18817 | 8 | Diffuse large B-cell lymphoma | HBL-1 | ivr | HS | MLN120B | 11 865 | 51 |
40 | GSE34228 | 26 | Lung adenocarcinoma | PC9 | ivr | HS | Gefitinib | 30 565 | 73 |
41 | GSE21245 | 10 | Pancreatic adenocarcinoma | LNCaP | ivr | HS | Dihydrotestosterone miRNA array | 143 | 188 |
Dihydrotestosterone miRNA array | 13 636 | 93 | |||||||
42 | GSE34243 | 17 | N/A | Pgk12.1 | ivr | MM | Differentiation induction | 343 738 | 49 |
43 | GSE45958 | 8 | Breast cancer | Control | ivr | HS | 2gy Radiation | 56 560 | 44 |
6gy Radiation | 27191 | 46 | |||||||
R6gy | 43 650 | 46 | |||||||
44 | GSE76368 | 8 | Breast cancer | MCF-7 | ivr | HS | Starvation | 3229 | 51 |
45 | GSE84096 | 11 | Non-small cell lung cancer | NCI-H1975 | ev | HS | EGF | 9443 | 90 |
8 | Control | 7059 | 64 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
37 | GSE15523 | 8 | Skin cancer | BJ NMyc | ivr | HS | N-MycER(delta-MbII) | 3875 | 44 |
N-MycER | 2741 | 54 | |||||||
38 | GSE17708 | 9 | Lung adenocarcinoma | A549 | ivr | HS | TGFb1 | 20 296 | 57 |
39 | GSE18817 | 8 | Diffuse large B-cell lymphoma | HBL-1 | ivr | HS | MLN120B | 11 865 | 51 |
40 | GSE34228 | 26 | Lung adenocarcinoma | PC9 | ivr | HS | Gefitinib | 30 565 | 73 |
41 | GSE21245 | 10 | Pancreatic adenocarcinoma | LNCaP | ivr | HS | Dihydrotestosterone miRNA array | 143 | 188 |
Dihydrotestosterone miRNA array | 13 636 | 93 | |||||||
42 | GSE34243 | 17 | N/A | Pgk12.1 | ivr | MM | Differentiation induction | 343 738 | 49 |
43 | GSE45958 | 8 | Breast cancer | Control | ivr | HS | 2gy Radiation | 56 560 | 44 |
6gy Radiation | 27191 | 46 | |||||||
R6gy | 43 650 | 46 | |||||||
44 | GSE76368 | 8 | Breast cancer | MCF-7 | ivr | HS | Starvation | 3229 | 51 |
45 | GSE84096 | 11 | Non-small cell lung cancer | NCI-H1975 | ev | HS | EGF | 9443 | 90 |
8 | Control | 7059 | 64 |
SL . | GEO accession . | Time point . | Cancer type . | Cell line . | ORG . | SP . | Condition . | # of DRG . | # of GRM . |
---|---|---|---|---|---|---|---|---|---|
37 | GSE15523 | 8 | Skin cancer | BJ NMyc | ivr | HS | N-MycER(delta-MbII) | 3875 | 44 |
N-MycER | 2741 | 54 | |||||||
38 | GSE17708 | 9 | Lung adenocarcinoma | A549 | ivr | HS | TGFb1 | 20 296 | 57 |
39 | GSE18817 | 8 | Diffuse large B-cell lymphoma | HBL-1 | ivr | HS | MLN120B | 11 865 | 51 |
40 | GSE34228 | 26 | Lung adenocarcinoma | PC9 | ivr | HS | Gefitinib | 30 565 | 73 |
41 | GSE21245 | 10 | Pancreatic adenocarcinoma | LNCaP | ivr | HS | Dihydrotestosterone miRNA array | 143 | 188 |
Dihydrotestosterone miRNA array | 13 636 | 93 | |||||||
42 | GSE34243 | 17 | N/A | Pgk12.1 | ivr | MM | Differentiation induction | 343 738 | 49 |
43 | GSE45958 | 8 | Breast cancer | Control | ivr | HS | 2gy Radiation | 56 560 | 44 |
6gy Radiation | 27191 | 46 | |||||||
R6gy | 43 650 | 46 | |||||||
44 | GSE76368 | 8 | Breast cancer | MCF-7 | ivr | HS | Starvation | 3229 | 51 |
45 | GSE84096 | 11 | Non-small cell lung cancer | NCI-H1975 | ev | HS | EGF | 9443 | 90 |
8 | Control | 7059 | 64 |
References
Author notes
Citation details: Patra,B.G., Soltanalizadeh,B., Deng,N., et al., An informatics research platform to make public gene expression time-course datasets reusable for more scientific discoveries. Database (2020) Vol. 00: article ID baaa074; doi:10.1093/database/baaa074